ESMO 2021 – Ian Chau
Ian Chau depicts the most interesting trial results in the field of esophageal cancer at the ESMO 2021 congress, gives an outlook on personalized approaches in the setting of esophageal squamous-cell carcinoma with regard to biomarkers for checkpoint inhibitors as well as potential further improvements of the prognosis of patients with esophageal cancer.
Here is the full ESMO 2021 Solid Tumors report.
More posts
Highlights in cervical cancer
In 2020, more than 600,000 new cases of cervical cancer were diagnosed. Its mortality rate reached 57 % with more than 340,000 deaths; cervical cancer was the ninth leading cause of cancer-related death worldwide and therefore a concerning global health issue. In young women (aged 15 to 44 years), it is the second most common cancer and cause of cancer death.
Novel approaches in gastric/gastroesophageal cancer
Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Although gastroesophageal junction (GEJ) cancer, a form of gastric cancer arising in the area of the digestive tract where esophagus and stomach connect, has a lower prevalence than GC, it is continuously rising.
Colorectal cancer – personalized medicine for a heterogeneous disease
Metastatic colorectal cancer (mCRC), a major cause of death in the Western world, continuous to have a 5-year survival rate below 15 %, with microsatellite stable (MSS) mCRC representing the greatest clinical challenge due to its poorly characterized immune microenvironment and immune response.
New horizons in colorectal cancer
Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. About 20 % of CRC patients are diagnosed at the metastatic stage (mCRC), with a 5-year survival rate of 14 %.
Preface
For the second time, the ESMO scientific meeting took place virtually from 16th - 21st September 2021. Despite the challenges of the pandemic, the ESMO committee received an increased number of submitted abstracts compared to last year.
